Clinical Trials
17 trialsNCT07055477 2026-05-22
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT05838599 2026-05-01
Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides
Northwestern University
Phase EARLY_PHASE1 Recruiting
NCT06854653 2026-04-29
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
Prescient Therapeutics, Ltd.
Phase 2 Recruiting
NCT05680558 2026-04-27
Photopheresis in Early-stage Mycosis Fungoides
Columbia University
Phase 2 Recruiting
NCT03398161 2026-04-15
Ultra Low Dose Radiation Therapy in Treating Patients With Mycosis Fungoides
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03017820 2026-04-13
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Mayo Clinic
Phase 1 Recruiting
NCT06508463 2026-04-13
Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
Mayo Clinic
Phase 1 Recruiting
NCT05414500 2026-04-09
Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides
University of Alabama at Birmingham
Phase 1 Recruiting
NCT03587844 2026-04-03
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06470451 2026-04-03
FLASH2
Soligenix
Phase 3 Recruiting
NCT05296304 2026-02-04
A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT05357794 2026-01-12
Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06716658 2025-11-18
JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting
NCT04930653 2025-10-14
Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma
City of Hope Medical Center
Phase 2 Recruiting
NCT04234048 2025-09-22
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
SciTech Development, Inc.
Phase 1 Recruiting
NCT00935090 2025-07-08
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Barbara Ann Karmanos Cancer Institute
Recruiting
NCT04256018 2025-07-02
Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome
Stanford University
Phase 2 Recruiting